{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_code in Code Literal (approximate match)
Status:
US Approved Rx
(2001)
Source:
BLA103948
(2001)
Source URL:
First approved in 2001
Source:
BLA103948
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
BLA103846
(2000)
Source URL:
First approved in 2000
Source:
BLA103846
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
Source:
BLA761064
(2017)
Source URL:
First approved in 1997
Source:
BLA103705
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1986)
Source:
BLA103132
(1986)
Source URL:
First approved in 1986
Source:
BLA103132
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02888106: Phase 2 Interventional Completed Chronic Viral Hepatitis B With Delta-agent
(2016)
Source URL:
Class:
PROTEIN
HBVPRES/2-48CONS-MYR (known as Bulevirtide or Myrcludex B) was developed as an agent bind and inactivate the hepatocyte surface protein sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP). By blocking NTCP, the drug misdirects hepatitis B virus (HBV) and co-infecting hepatitis D virus (HDV) to an unproductive pathway and thereby prevents infection of the cell. Because NTCP is involved in the bile acid transport cycle, the blockade of this target by myrcludex B can potentially be used for the treatment of various metabolic and inflammatory diseases. Myrcludex B is going to participate in phase 3 trial for patients with chronic hepatitis D, however, the study is not yet recruited. The drug successfully completed phase II clinical trial for the patients with chronic hepatitis B and D. In addition, myrcludex B has been studied during preclinical research as a potential treatment of dyslipidemias, non-alcoholic steatohepatitis; primary biliary cirrhosis.
Status:
Possibly Marketed Outside US
First approved in 2016
Source:
BLA125582
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
BLA125426
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Alprolix by Bioverativ Canada Inc [Canada]
Source URL:
First approved in 2014
Source:
BLA125444
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
BLA103665
Source URL:
Class:
PROTEIN
